1. How is FUJIFILM addressing the growing gap between scientific breakthrough and manufacturing scalability in advanced biologics?
Response: The gap between scientific breakthrough and manufacturing scalability is widening as pipelines expand beyond established biologics into newer, more complex modalities. These products often bring specialised process, analytical, containment, and supply requirements, while their clinical and commercial demand can be difficult to predict. We address that complexity by bringing development and manufacturing together earlier – aligning the molecule, process, analytical strategy, regulatory pathway, and future scale from the outset. Our connected kojoX network provides access to deep expertise, common platforms, and harmonised ways of working across sites and scales. This helps preserve process knowledge, reduce technology-transfer risk, and give customers flexibility as their program evolves. The goal is not simply to add capacity, but to create a more adaptable and predictable path from breakthrough to commercial supply for increasingly complex therapies.
2. What role do you see for AI-enabled process monitoring and predictive analytics in biologics production, and what solutions are you bringing to the market?
Response: AI is most valuable when it strengthens decision-making and execution rather than being treated as a standalone solution. In biologics production, practical applications include detecting process trends earlier, improving forecasting, and integrated planning, supporting quality review, enabling predictive maintenance, and making technology transfer more consistent by applying data and institutional knowledge. In development, advanced modelling can also increase in silico experimentation, reducing some wet-lab work, time, and cost. Our direction is to combine these capabilities with connected manufacturing networks and common platforms so teams and customers can gain earlier insight, anticipate risk, and respond faster. The foundation matters: validated data, strong governance, and expert oversight are essential. AI should augment human judgement and give our experts more time to solve complex customer challenges.
3. How is FUJIFILM navigating disjointed regulatory pathways, and working with other companies or investments for harmonised approval frameworks?
Response: Regulatory fragmentation cannot be solved by any one company, so we engage early and work across regulators, customers, and industry groups to turn policy ambition into practical execution. The goal should be greater predictability, shared standards, and coordinated implementation across regions – so that you’re not starting from zero every time you want to enter a new market. We support that through harmonized platforms, common quality systems, and connected manufacturing approaches that can make technology transfer and regulatory alignment faster and lower risk. Importantly, our Holly Springs, North Carolina, USA facility was selected as one of only seven participants in the FDA PreCheck Pilot Program, which enables earlier FDA engagement to improve manufacturing readiness, regulatory predictability, and the facility inspection process. This participation gives us an opportunity to help shape a more efficient model for bringing critical medicines to patients. Ultimately, harmonisation should make regions easier to invest in, faster to scale in, and more reliable as bases for global supply.
4. What insights or partnerships have you gained from participating in industry dialogues at events like CPHI Milan?
Response: Our discussions with sponsors at events like CPHI Milan reinforce that they are looking for more than capacity. They want strategic partners who engage early, align on outcomes, provide transparency, and help plan for multiple scenarios across the product lifecycle. The strongest discussions are moving the industry from transactional outsourcing toward integrated partnerships built on trust, shared risk management, and clear governance. They also show broad recognition that supply resilience must be designed in – from geographic optionality and local-for-local strategies to easier technology transfer across connected networks. Events such as CPHI bring innovators, manufacturers, suppliers, policymakers, and technology partners into the same conversation. Those connections help identify where common standards, data collaboration, and coordinated investment can remove friction and improve reliable patient access.
5. What emerging manufacturing challenges do you anticipate in the next 5 years for advanced biologics?
Response: Over the next 5 years, manufacturers will need to support a much broader mix of modalities, often for smaller patient populations and with limited visibility into demand. That creates a different operating challenge: facilities, equipment, and teams must accommodate highly varied processes and batch profiles without adding unnecessary cost or complexity. Rapid scientific change also increases the risk that technologies and capacity plans become outdated before assets reach full utilisation. AI can help manufacturers navigate this complexity by improving demand forecasting, identifying process trends earlier and enabling more responsive planning – but its value will depend on connected, high-quality data foundation and appropriate governance. At the same time, specialized raw materials, single-source components and a limited pool of experienced technical talent may constrain execution. The key will be balancing flexibility with enough standardization to maintain quality, speed, and economic sustainability as the pipeline continues to evolve.
